Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)

Competitors to Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)

Amgen Inc. 

Amgen, a biotechnology giant, develops and manufactures a wide range of therapies, including those for rare diseases. While Quoin Pharmaceuticals is focused on niche markets, Amgen's vast resources, extensive product offerings, and established market presence create a significant competitive challenge. Amgen’s stronger financial backing allows for greater investment in research and clinical trials, giving it a notable competitive advantage over Quoin.

Blueprint Medicines Corporation 

Blueprint Medicines develops targeted therapies for genomically defined cancers and rare diseases. Both Quoin Pharmaceuticals and Blueprint Medicines aim to address unmet medical needs, but Blueprint's focus on precision medicine and a strong pipeline of advanced clinical trials gives it a competitive edge. Their established relationships with healthcare professionals and robust funding also contribute to their leadership position in the market.

Regenxbio Inc. 

Regenxbio focuses on the development of gene therapy solutions for the treatment of various diseases, including rare genetic disorders and eye diseases. Quoin Pharmaceuticals specializes in developing proprietary medications for rare diseases, creating a competitive landscape where both companies target niche markets. However, Regenxbio has a more established product pipeline and greater experience in gene therapy, which provides it a competitive advantage in research and development, as well as regulatory approvals.

Sarepta Therapeutics, Inc. 

Sarepta specializes in genetic medicine, particularly in therapies for rare diseases such as Duchenne muscular dystrophy. Both companies are engaged in addressing rare diseases, but Sarepta's advanced gene therapy technologies and established partnerships with research institutions provide them with a competitive edge. Their successful commercialization of therapies offers a stronger foothold in the market compared to Quoin’s emerging status.

Ultragenyx Pharmaceutical Inc. 

Ultragenyx focuses on developing innovative products for rare diseases. Like Quoin Pharmaceuticals, they work in the same sector but have a broader pipeline and experience with multiple product launches. The competitive advantage lies in Ultragenyx’s established relationships with regulatory bodies and healthcare providers, along with their comprehensive clinical trial approaches which fosters credibility and success in securing approvals for new therapies.